Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18 F ‐labeled rBC2LCN lectin
Advancement in early detection modalities will greatly improve the overall prognoses of pancreatic ductal adenocarcinoma (PDAC). For this purpose, we report a novel class of tumor‐specific probes for positron emission tomography (PET) based on targeting cell surface glycans. The PDAC‐targeting abili...
Uloženo v:
| Vydáno v: | Cancer science Ročník 114; číslo 8; s. 3364 - 3373 |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
01.08.2023
|
| Témata: | |
| ISSN: | 1347-9032, 1349-7006, 1349-7006 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Advancement in early detection modalities will greatly improve the overall prognoses of pancreatic ductal adenocarcinoma (PDAC). For this purpose, we report a novel class of tumor‐specific probes for positron emission tomography (PET) based on targeting cell surface glycans. The PDAC‐targeting ability of rBC2LCN lectin, combined with fluorine‐18 (
18
F) ([
18
F]FB‐rBC2LCN), resulted in reproducible, high‐contrast PET imaging of tumors in a PDAC xenograft mouse model. [
18
F]
N
‐succinimidyl‐4‐fluorobenzoate ([
18
F]SFB) was conjugated to rBC2LCN, and [
18
F]FB‐rBC2LCN was successfully prepared with a radiochemical purity >95%. Cell binding and uptake revealed that [
18
F]FB‐rBC2LCN binds to H‐type‐3‐positive Capan‐1 pancreatic cancer cells. As early as 60 min after [
18
F]FB‐rBC2LCN (0.34 ± 0.15 MBq) injection into the tail vein of nude mice subcutaneously bearing Capan‐1 tumors, tumor uptake was high (6.6 ± 1.8 %ID/g), and the uptake increased over time (8.8 ± 1.9 %ID/g and 11 ± 3.2 %ID/g at 150 and 240 min after injection, respectively). Tumor‐to‐muscle ratios increased over time, up to 19 ± 1.8 at 360 min. High‐contrast PET imaging of tumors relative to background muscle was also achieved as early as 60 min after injection of [
18
F]FB‐rBC2LCN (0.66 ± 0.12 MBq) and continued to increase up to 240 min. Our
18
F‐labeled rBC2LCN lectin warrants further clinical development to improve the accuracy and sensitivity of early‐stage pancreatic cancer detection. |
|---|---|
| AbstractList | Advancement in early detection modalities will greatly improve the overall prognoses of pancreatic ductal adenocarcinoma (PDAC). For this purpose, we report a novel class of tumor-specific probes for positron emission tomography (PET) based on targeting cell surface glycans. The PDAC-targeting ability of rBC2LCN lectin, combined with fluorine-18 (
F) ([
F]FB-rBC2LCN), resulted in reproducible, high-contrast PET imaging of tumors in a PDAC xenograft mouse model. [
F]N-succinimidyl-4-fluorobenzoate ([
F]SFB) was conjugated to rBC2LCN, and [
F]FB-rBC2LCN was successfully prepared with a radiochemical purity >95%. Cell binding and uptake revealed that [
F]FB-rBC2LCN binds to H-type-3-positive Capan-1 pancreatic cancer cells. As early as 60 min after [
F]FB-rBC2LCN (0.34 ± 0.15 MBq) injection into the tail vein of nude mice subcutaneously bearing Capan-1 tumors, tumor uptake was high (6.6 ± 1.8 %ID/g), and the uptake increased over time (8.8 ± 1.9 %ID/g and 11 ± 3.2 %ID/g at 150 and 240 min after injection, respectively). Tumor-to-muscle ratios increased over time, up to 19 ± 1.8 at 360 min. High-contrast PET imaging of tumors relative to background muscle was also achieved as early as 60 min after injection of [
F]FB-rBC2LCN (0.66 ± 0.12 MBq) and continued to increase up to 240 min. Our
F-labeled rBC2LCN lectin warrants further clinical development to improve the accuracy and sensitivity of early-stage pancreatic cancer detection. Advancement in early detection modalities will greatly improve the overall prognoses of pancreatic ductal adenocarcinoma (PDAC). For this purpose, we report a novel class of tumor-specific probes for positron emission tomography (PET) based on targeting cell surface glycans. The PDAC-targeting ability of rBC2LCN lectin, combined with fluorine-18 (18 F) ([18 F]FB-rBC2LCN), resulted in reproducible, high-contrast PET imaging of tumors in a PDAC xenograft mouse model. [18 F]N-succinimidyl-4-fluorobenzoate ([18 F]SFB) was conjugated to rBC2LCN, and [18 F]FB-rBC2LCN was successfully prepared with a radiochemical purity >95%. Cell binding and uptake revealed that [18 F]FB-rBC2LCN binds to H-type-3-positive Capan-1 pancreatic cancer cells. As early as 60 min after [18 F]FB-rBC2LCN (0.34 ± 0.15 MBq) injection into the tail vein of nude mice subcutaneously bearing Capan-1 tumors, tumor uptake was high (6.6 ± 1.8 %ID/g), and the uptake increased over time (8.8 ± 1.9 %ID/g and 11 ± 3.2 %ID/g at 150 and 240 min after injection, respectively). Tumor-to-muscle ratios increased over time, up to 19 ± 1.8 at 360 min. High-contrast PET imaging of tumors relative to background muscle was also achieved as early as 60 min after injection of [18 F]FB-rBC2LCN (0.66 ± 0.12 MBq) and continued to increase up to 240 min. Our 18 F-labeled rBC2LCN lectin warrants further clinical development to improve the accuracy and sensitivity of early-stage pancreatic cancer detection.Advancement in early detection modalities will greatly improve the overall prognoses of pancreatic ductal adenocarcinoma (PDAC). For this purpose, we report a novel class of tumor-specific probes for positron emission tomography (PET) based on targeting cell surface glycans. The PDAC-targeting ability of rBC2LCN lectin, combined with fluorine-18 (18 F) ([18 F]FB-rBC2LCN), resulted in reproducible, high-contrast PET imaging of tumors in a PDAC xenograft mouse model. [18 F]N-succinimidyl-4-fluorobenzoate ([18 F]SFB) was conjugated to rBC2LCN, and [18 F]FB-rBC2LCN was successfully prepared with a radiochemical purity >95%. Cell binding and uptake revealed that [18 F]FB-rBC2LCN binds to H-type-3-positive Capan-1 pancreatic cancer cells. As early as 60 min after [18 F]FB-rBC2LCN (0.34 ± 0.15 MBq) injection into the tail vein of nude mice subcutaneously bearing Capan-1 tumors, tumor uptake was high (6.6 ± 1.8 %ID/g), and the uptake increased over time (8.8 ± 1.9 %ID/g and 11 ± 3.2 %ID/g at 150 and 240 min after injection, respectively). Tumor-to-muscle ratios increased over time, up to 19 ± 1.8 at 360 min. High-contrast PET imaging of tumors relative to background muscle was also achieved as early as 60 min after injection of [18 F]FB-rBC2LCN (0.66 ± 0.12 MBq) and continued to increase up to 240 min. Our 18 F-labeled rBC2LCN lectin warrants further clinical development to improve the accuracy and sensitivity of early-stage pancreatic cancer detection. Advancement in early detection modalities will greatly improve the overall prognoses of pancreatic ductal adenocarcinoma (PDAC). For this purpose, we report a novel class of tumor‐specific probes for positron emission tomography (PET) based on targeting cell surface glycans. The PDAC‐targeting ability of rBC2LCN lectin, combined with fluorine‐18 ( 18 F) ([ 18 F]FB‐rBC2LCN), resulted in reproducible, high‐contrast PET imaging of tumors in a PDAC xenograft mouse model. [ 18 F] N ‐succinimidyl‐4‐fluorobenzoate ([ 18 F]SFB) was conjugated to rBC2LCN, and [ 18 F]FB‐rBC2LCN was successfully prepared with a radiochemical purity >95%. Cell binding and uptake revealed that [ 18 F]FB‐rBC2LCN binds to H‐type‐3‐positive Capan‐1 pancreatic cancer cells. As early as 60 min after [ 18 F]FB‐rBC2LCN (0.34 ± 0.15 MBq) injection into the tail vein of nude mice subcutaneously bearing Capan‐1 tumors, tumor uptake was high (6.6 ± 1.8 %ID/g), and the uptake increased over time (8.8 ± 1.9 %ID/g and 11 ± 3.2 %ID/g at 150 and 240 min after injection, respectively). Tumor‐to‐muscle ratios increased over time, up to 19 ± 1.8 at 360 min. High‐contrast PET imaging of tumors relative to background muscle was also achieved as early as 60 min after injection of [ 18 F]FB‐rBC2LCN (0.66 ± 0.12 MBq) and continued to increase up to 240 min. Our 18 F‐labeled rBC2LCN lectin warrants further clinical development to improve the accuracy and sensitivity of early‐stage pancreatic cancer detection. |
| Author | Tateno, Hiroaki Hatano, Kentaro Shimomura, Osamu Louphrasitthiphol, Pakavarin Kuroda, Yukihito Oda, Tatsuya Mathis, Bryan J. |
| Author_xml | – sequence: 1 givenname: Yukihito orcidid: 0000-0002-6920-6731 surname: Kuroda fullname: Kuroda, Yukihito organization: Department of Gastrointestinal and Hepato‐Biliary‐Pancreatic Surgery, Faculty of Medicine University of Tsukuba Tsukuba Japan – sequence: 2 givenname: Tatsuya orcidid: 0000-0001-6115-0158 surname: Oda fullname: Oda, Tatsuya organization: Department of Gastrointestinal and Hepato‐Biliary‐Pancreatic Surgery, Faculty of Medicine University of Tsukuba Tsukuba Japan – sequence: 3 givenname: Osamu surname: Shimomura fullname: Shimomura, Osamu organization: Department of Gastrointestinal and Hepato‐Biliary‐Pancreatic Surgery, Faculty of Medicine University of Tsukuba Tsukuba Japan – sequence: 4 givenname: Pakavarin surname: Louphrasitthiphol fullname: Louphrasitthiphol, Pakavarin organization: Department of Gastrointestinal and Hepato‐Biliary‐Pancreatic Surgery, Faculty of Medicine University of Tsukuba Tsukuba Japan – sequence: 5 givenname: Bryan J. surname: Mathis fullname: Mathis, Bryan J. organization: International Medical Center University of Tsukuba Hospital Tsukuba Japan – sequence: 6 givenname: Hiroaki surname: Tateno fullname: Tateno, Hiroaki organization: Cellular and Molecular Biotechnology Research Institute National Institute of Advanced Industrial Science and Technology Tsukuba Japan – sequence: 7 givenname: Kentaro orcidid: 0000-0001-8154-3119 surname: Hatano fullname: Hatano, Kentaro organization: Department of Applied Molecular Imaging, Faculty of Medicine University of Tsukuba Tsukuba Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37203465$$D View this record in MEDLINE/PubMed |
| BookMark | eNplkbtOxDAQRS0E4l3wA8glFAE_E4cOVryk1dLQW44zCUHeONhZpK3gE_hGvgQvCw1MM1fWmStd3z202fseEDqi5IymObcmnlGpRL6BdikXZVYQkm9-6yIrCWc7aC_GZ0J4LkqxjXZ4wQgXudxFbzP_Cg4PPnZj8D2GeRdjl8To574NZnha4m5u2q5v8WhCC-NKWXAOx0VojAXcuqU1fcSND3gwvQ1gxs7i9GYhXGCq8A3-fP9wpgIHNQ5XEzadzLADm7wO0FZjXITDn72PHm-uHyd32fTh9n5yOc0s5URmnElla1ox0SjGGyF4IeoCmCGslCCrSsqak0KBJTUowVQplKGWVlQ2QBXfRydr2yH4lwXEUaecqxSmB7-ImimaFzklqkjo8Q-6qOZQ6yGk_GGpf_8sAedrwAYfY4BG225MkX0_BtM5TYletaJTK_q7lXRx-ufi1_Q_-wU4lI2t |
| CitedBy_id | crossref_primary_10_2174_0113895575375382250408143606 crossref_primary_10_1007_s12149_024_01999_1 crossref_primary_10_1038_s41598_025_02404_1 |
| Cites_doi | 10.1016/j.bbrc.2020.11.087 10.1002/pmic.201300387 10.2967/jnumed.112.114926 10.1016/j.nucmedbio.2004.09.005 10.1001/jama.2021.13027 10.1159/000161009 10.1038/nrc3982 10.2967/jnumed.113.119867 10.3390/ph7040392 10.1016/j.ejso.2014.03.016 10.1007/s00259-010-1497-y 10.1080/1354750X.2020.1725786 10.1007/s13566-013-0130-7 10.1038/nrgastro.2013.42 10.1158/2159-8290.CD-13-0760 10.1053/j.gastro.2013.01.076 10.1007/s10120-022-01312-x 10.1111/cas.15023 10.1593/tlo.12166 10.1007/s00261-017-1374-2 10.1038/nbt1141 10.1038/nature06917 10.1053/j.gastro.2012.01.005 10.2967/jnumed.112.105460 10.2967/jnumed.107.047787 10.1016/j.trsl.2019.08.002 10.1007/s00726-012-1216-z 10.2967/jnumed.117.199901 10.1016/j.str.2009.10.021 10.1111/cas.14687 10.1016/j.bbrc.2019.05.108 10.1038/nri2747 10.1038/s41419-018-0367-6 10.1073/pnas.1917947117 10.1016/j.jconrel.2012.04.043 10.1007/s10555-014-9505-5 10.1093/glycob/cwh122 10.3389/fmed.2021.668697 10.1002/ijc.34362 10.3390/molecules26123492 10.1021/acs.molpharmaceut.5b00626 10.1016/j.ejim.2013.06.012 10.1038/nprot.2006.264 10.1073/pnas.0811481106 10.1073/pnas.1812938115 10.1016/j.addr.2010.09.004 10.1038/nrgastro.2016.144 10.1016/j.nucmedbio.2014.10.009 10.1016/j.cgh.2012.12.033 10.1021/bc500475e 10.2967/jnumed.107.043216 10.1158/1078-0432.CCR-17-0664 10.1111/joim.12465 10.1038/sj.jcbfm.9600493 10.1158/1535-7163.MCT-17-0232 10.1016/j.apradiso.2005.03.005 10.18632/oncotarget.6060 |
| ContentType | Journal Article |
| Copyright | 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. |
| Copyright_xml | – notice: 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1111/cas.15846 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1349-7006 |
| EndPage | 3373 |
| ExternalDocumentID | 37203465 10_1111_cas_15846 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: JSPS KAKENHI grantid: JP19H05557 – fundername: JSPS KAKENHI grantid: JP20KA20467 |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 24P 29B 2WC 31~ 36B 3O- 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 88E 8FE 8FH 8FI 8FJ 8UM 930 A01 A03 AAFWJ AAMMB AAYXX AAZKR ABCQN ABEML ABUWG ACCMX ACSCC ACXQS ADBBV ADKYN ADPDF ADZMN AEFGJ AENEX AFBPY AFEBI AFFHD AFFNX AFKRA AFPKN AFZJQ AGXDD AIDQK AIDYY ALMA_UNASSIGNED_HOLDINGS AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BFHJK BHPHI BY8 CAG CCPQU CITATION COF CS3 D-6 D-7 D-E D-F DR2 DU5 E3Z EBS EJD EMB EMOBN EX3 F00 F01 F04 F5P FIJ FYUFA GODZA GROUPED_DOAJ HCIFZ HF~ HMCUK HOLLA HYE HZI HZ~ IAO IHR ITC IX1 J0M K.9 K48 KQ8 LC2 LC3 LH4 LK8 LP6 LP7 LW6 M1P M7P MK4 N04 N05 N9A O8X O9- OIG OK1 OVD P2P P2X P2Z P4B P4D PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PROAC PSQYO Q11 ROL RPM RX1 SJN SUPJJ SV3 TEORI UB1 UKHRP W8V WIN WOW WQJ WXI X7M XG1 ZXP ~IA ~WT ALUQN CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c1305-3258cd1b24f823f44374d7e2a0295e5bb55d3078ec0de8428948a1c1b15fe183 |
| ISSN | 1347-9032 1349-7006 |
| IngestDate | Sun Nov 09 11:56:34 EST 2025 Mon Jul 21 05:38:23 EDT 2025 Tue Nov 18 20:51:19 EST 2025 Sat Nov 29 02:47:07 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | fluorine-18 pancreatic cancer molecular imaging lectin PET |
| Language | English |
| License | 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c1305-3258cd1b24f823f44374d7e2a0295e5bb55d3078ec0de8428948a1c1b15fe183 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-6115-0158 0000-0002-6920-6731 0000-0001-8154-3119 |
| PMID | 37203465 |
| PQID | 2816761087 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_2816761087 pubmed_primary_37203465 crossref_citationtrail_10_1111_cas_15846 crossref_primary_10_1111_cas_15846 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-08-00 2023-Aug 20230801 |
| PublicationDateYYYYMMDD | 2023-08-01 |
| PublicationDate_xml | – month: 08 year: 2023 text: 2023-08-00 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Cancer science |
| PublicationTitleAlternate | Cancer Sci |
| PublicationYear | 2023 |
| References | e_1_2_10_23_1 e_1_2_10_46_1 e_1_2_10_21_1 e_1_2_10_44_1 e_1_2_10_42_1 e_1_2_10_40_1 Cummings RD (e_1_2_10_48_1) 2015 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_53_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_39_1 e_1_2_10_55_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_37_1 e_1_2_10_57_1 e_1_2_10_58_1 e_1_2_10_13_1 e_1_2_10_34_1 e_1_2_10_11_1 e_1_2_10_32_1 e_1_2_10_30_1 Vanek P (e_1_2_10_5_1) 2022; 10 e_1_2_10_61_1 e_1_2_10_29_1 e_1_2_10_27_1 e_1_2_10_25_1 e_1_2_10_24_1 e_1_2_10_45_1 Huhalov A (e_1_2_10_51_1) 2004; 48 e_1_2_10_22_1 e_1_2_10_43_1 e_1_2_10_20_1 e_1_2_10_41_1 e_1_2_10_52_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_54_1 e_1_2_10_17_1 e_1_2_10_38_1 e_1_2_10_56_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_36_1 e_1_2_10_12_1 e_1_2_10_35_1 e_1_2_10_9_1 e_1_2_10_59_1 e_1_2_10_10_1 e_1_2_10_33_1 e_1_2_10_31_1 e_1_2_10_50_1 e_1_2_10_60_1 e_1_2_10_62_1 e_1_2_10_28_1 e_1_2_10_49_1 e_1_2_10_26_1 e_1_2_10_47_1 |
| References_xml | – ident: e_1_2_10_26_1 doi: 10.1016/j.bbrc.2020.11.087 – ident: e_1_2_10_24_1 doi: 10.1002/pmic.201300387 – ident: e_1_2_10_33_1 doi: 10.2967/jnumed.112.114926 – start-page: 611 volume-title: Essentials of Glycobiology year: 2015 ident: e_1_2_10_48_1 – ident: e_1_2_10_35_1 doi: 10.1016/j.nucmedbio.2004.09.005 – ident: e_1_2_10_2_1 doi: 10.1001/jama.2021.13027 – ident: e_1_2_10_40_1 doi: 10.1159/000161009 – ident: e_1_2_10_23_1 doi: 10.1038/nrc3982 – volume: 10 start-page: 10 year: 2022 ident: e_1_2_10_5_1 article-title: Current screening strategies for pancreatic cancer publication-title: Biomedicine – ident: e_1_2_10_18_1 doi: 10.2967/jnumed.113.119867 – volume: 48 start-page: 279 year: 2004 ident: e_1_2_10_51_1 article-title: Engineered single chain antibody fragments for radioimmunotherapy publication-title: Q J Nucl Med Mol Imaging – ident: e_1_2_10_41_1 doi: 10.3390/ph7040392 – ident: e_1_2_10_13_1 doi: 10.1016/j.ejso.2014.03.016 – ident: e_1_2_10_56_1 doi: 10.1007/s00259-010-1497-y – ident: e_1_2_10_39_1 doi: 10.1080/1354750X.2020.1725786 – ident: e_1_2_10_10_1 doi: 10.1007/s13566-013-0130-7 – ident: e_1_2_10_14_1 doi: 10.1038/nrgastro.2013.42 – ident: e_1_2_10_25_1 doi: 10.1158/2159-8290.CD-13-0760 – ident: e_1_2_10_8_1 doi: 10.1053/j.gastro.2013.01.076 – ident: e_1_2_10_62_1 doi: 10.1007/s10120-022-01312-x – ident: e_1_2_10_38_1 doi: 10.1111/cas.15023 – ident: e_1_2_10_60_1 doi: 10.1593/tlo.12166 – ident: e_1_2_10_55_1 doi: 10.1007/s00261-017-1374-2 – ident: e_1_2_10_52_1 doi: 10.1038/nbt1141 – ident: e_1_2_10_31_1 doi: 10.1038/nature06917 – ident: e_1_2_10_4_1 doi: 10.1053/j.gastro.2012.01.005 – ident: e_1_2_10_17_1 doi: 10.2967/jnumed.112.105460 – ident: e_1_2_10_15_1 doi: 10.2967/jnumed.107.047787 – ident: e_1_2_10_6_1 doi: 10.1016/j.trsl.2019.08.002 – ident: e_1_2_10_45_1 doi: 10.1007/s00726-012-1216-z – ident: e_1_2_10_42_1 doi: 10.2967/jnumed.117.199901 – ident: e_1_2_10_27_1 doi: 10.1016/j.str.2009.10.021 – ident: e_1_2_10_54_1 doi: 10.1111/cas.14687 – ident: e_1_2_10_61_1 doi: 10.1016/j.bbrc.2019.05.108 – ident: e_1_2_10_37_1 doi: 10.1038/nri2747 – ident: e_1_2_10_58_1 doi: 10.1038/s41419-018-0367-6 – ident: e_1_2_10_36_1 doi: 10.1073/pnas.1917947117 – ident: e_1_2_10_19_1 doi: 10.1016/j.jconrel.2012.04.043 – ident: e_1_2_10_20_1 doi: 10.1007/s10555-014-9505-5 – ident: e_1_2_10_29_1 doi: 10.1093/glycob/cwh122 – ident: e_1_2_10_11_1 doi: 10.3389/fmed.2021.668697 – ident: e_1_2_10_30_1 doi: 10.1002/ijc.34362 – ident: e_1_2_10_47_1 doi: 10.3390/molecules26123492 – ident: e_1_2_10_21_1 doi: 10.1021/acs.molpharmaceut.5b00626 – ident: e_1_2_10_9_1 doi: 10.1016/j.ejim.2013.06.012 – ident: e_1_2_10_43_1 doi: 10.1038/nprot.2006.264 – ident: e_1_2_10_50_1 doi: 10.1073/pnas.0811481106 – ident: e_1_2_10_59_1 doi: 10.1073/pnas.1812938115 – ident: e_1_2_10_53_1 doi: 10.1016/j.addr.2010.09.004 – ident: e_1_2_10_7_1 doi: 10.1038/nrgastro.2016.144 – ident: e_1_2_10_16_1 doi: 10.1016/j.nucmedbio.2014.10.009 – ident: e_1_2_10_12_1 doi: 10.1016/j.cgh.2012.12.033 – ident: e_1_2_10_44_1 doi: 10.1021/bc500475e – ident: e_1_2_10_46_1 doi: 10.2967/jnumed.107.043216 – ident: e_1_2_10_34_1 doi: 10.1158/1078-0432.CCR-17-0664 – ident: e_1_2_10_22_1 doi: 10.1111/joim.12465 – ident: e_1_2_10_49_1 doi: 10.1038/sj.jcbfm.9600493 – ident: e_1_2_10_28_1 doi: 10.1158/1535-7163.MCT-17-0232 – ident: e_1_2_10_3_1 – ident: e_1_2_10_32_1 doi: 10.1016/j.apradiso.2005.03.005 – ident: e_1_2_10_57_1 doi: 10.18632/oncotarget.6060 |
| SSID | ssj0036494 |
| Score | 2.4033628 |
| Snippet | Advancement in early detection modalities will greatly improve the overall prognoses of pancreatic ductal adenocarcinoma (PDAC). For this purpose, we report a... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 3364 |
| SubjectTerms | Animals Carcinoma, Pancreatic Ductal Cell Line, Tumor Humans Mice Mice, Nude Pancreatic Neoplasms Pancreatic Neoplasms - diagnostic imaging Positron-Emission Tomography - methods Radiopharmaceuticals |
| Title | Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18 F ‐labeled rBC2LCN lectin |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37203465 https://www.proquest.com/docview/2816761087 |
| Volume | 114 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1349-7006 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036494 issn: 1347-9032 databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1349-7006 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036494 issn: 1347-9032 databaseCode: M7P dateStart: 19880101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1349-7006 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036494 issn: 1347-9032 databaseCode: 7X7 dateStart: 19880101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1349-7006 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036494 issn: 1347-9032 databaseCode: BENPR dateStart: 19880101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1349-7006 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036494 issn: 1347-9032 databaseCode: PIMPY dateStart: 19880101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1349-7006 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036494 issn: 1347-9032 databaseCode: WIN dateStart: 20030101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Open Access customDbUrl: eissn: 1349-7006 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036494 issn: 1347-9032 databaseCode: 24P dateStart: 20030101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6lLUJcEM8SHtGCOCBZlrxrO7vmRqNGVEpNBBG0p2htr0lE4kROHLUn-An8LH4Hv4TZh50WqFQOXFbRxI_1zud5eXYGoZcZCxJQ47mbJjlzg1Smrsgiz428nCQ5oSTTdbY_Dlgc85OTaNhq_aj3wmxmrCj42Vm0_K-sBhowW22d_Qd2NxcFAvwGpsMIbIfxWoyPFxs5c3QyVgmsVf3cVEQMjMy5LU_tTOemN5FJA9fbblUIb1WVuYD3_PPsHBZcF2pwQFgYuzJV-WGp1F0lCXf6TpMmATgC3ZU55UGPDnqxoz4E2Hre2xIIqaoabeTIha9Hi0zbrqfVl-kEREsT8TXkkVivqvNGb3yYAK7mlW6M5LxbiXlV_zNYVIBJAU-8nkyXE9M0DGxjsRGlnYkNbFC_SaurZbEfMMCMDX_Kmha5zPO6lwS42YZqkcoviGPfNyXSrWr3fdM25Qq1oZrMEWWQbXVjnQ_wm8psEhlrFwpOHetTd9AeZWGkkgs_HcW1TQDTiEx7ZftItsaVyilr7nrZMrrC3dFmz-gOum39FfzG4OwuasniHrp5bDMy7qOvGm64hhuu4Ya3cMMWbriBG1ZwwxZu2MINA9zwFm7YwO01Jhz38c9v3y3MsIUZNjB7gEb9w1HvrWubergpmEuh69OQpxlJaJBz6udB4LMgY5IKj0ahDJMkDDPQO1ymXiY5OMdRwAVJSULCXIL-eYh2i0UhHyEc5UwEVFWj6kZBziQ4OuCO0Jx1ich4N2mjV_V6jlNb8F71XZmN_-BaG71oDl2aKi9_O-h5zZQxrKVaKVHIRbUaU05gEsTjrI32Dbeay6guUH7QDR9f5xZP0K3tm_AU7a7LSj5DN9LNeroqO2iHnTA98g7aOziMh-87OobUURnLQ6ANj46Hpx0NvV8gebp3 |
| linkProvider | Wiley-Blackwell |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Novel+positron+emission+tomography+imaging+targeting+cell+surface+glycans+for+pancreatic+cancer%3A+18+F+%E2%80%90labeled+rBC2LCN+lectin&rft.jtitle=Cancer+science&rft.au=Kuroda%2C+Yukihito&rft.au=Oda%2C+Tatsuya&rft.au=Shimomura%2C+Osamu&rft.au=Louphrasitthiphol%2C+Pakavarin&rft.date=2023-08-01&rft.issn=1347-9032&rft.eissn=1349-7006&rft.volume=114&rft.issue=8&rft.spage=3364&rft.epage=3373&rft_id=info:doi/10.1111%2Fcas.15846&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_cas_15846 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-9032&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-9032&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-9032&client=summon |